Wearable ECG Monitor Patent Landscape 2026
Wearable ECG Monitor Patent Landscape in 2026
The wearable ECG monitor patent field is heavily concentrated, with Bardy Diagnostics, Medtronic, and Philips together accounting for a dominant share of activity among the top hundred filers. Annual filing volume peaked in 2018 and has since eased, signaling a maturing competitive environment where incremental differentiation and adjacent technology moves are the primary strategic levers.
Bardy Diagnostics leads a concentrated but multi-tiered field
Bardy Diagnostics holds the top position among all ranked applicants, followed by Medtronic and Koninklijke Philips. These three leaders represent a clear first tier separated from the mid-tier filers that cluster between roughly 50 and 75 patent records.
The top five filers collectively account for 40% of the combined total of the hundred largest filers, a level of concentration that indicates a few well-resourced players have built substantial defensive portfolios while leaving meaningful room for focused challengers.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Bardy Diagnostics Inc. | 202 | |
| 2 | Medtronic Inc. | 137 | |
| 3 | Koninklijke Philips NV | 118 | |
| 4 | Medicomp Inc. | 73 | |
| 5 | AliveCor Inc. | 52 | |
| 6 | Zoll Medical Corporation | 35 | |
| 7 | VivaQuant LLC | 34 | |
| 8 | Spangler Scientific LLC | 30 | |
| 9 | Shanghai Lepu Cloudmed Co., Ltd. | 30 | |
| 10 | Spacelabs Healthcare LLC | 27 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | BodyMedia Inc. | 26 | |
| 12 | imec vzw | 22 | |
| 13 | Cardiac Pacemakers Inc. | 20 | |
| 14 | ResMed Sensor Technologies Ltd. | 20 | |
| 15 | Beth Israel Deaconess Medical Center Inc. | 20 | |
| 16 | Eko Health Inc. | 18 | |
| 17 | Virginia Commonwealth University | 18 | |
| 18 | Quantum Intech Inc. | 17 | |
| 19 | GE Precision Healthcare LLC | 17 | |
| 20 | The Board of Regents of the University of Oklahoma | 16 |
The leaders’ positions suggest deep investment in core cardiac monitoring claims; new entrants seeking freedom to operate should map their work carefully against these incumbents’ primary A61B 5 holdings before committing significant R&D resources.
Filing counts for 2025 and 2026 reflect publication lag and are likely undercounted; the apparent recent low should not be read as a reversal of the longer competitive engagement in this field. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2018 peak followed by moderation, with diagnosis hardware dominating the technology mix
The annual filing trend and the technology branch composition together reveal a field that mobilized quickly around clinical-grade wearable hardware and is now evolving toward informatics and connectivity layers.
Annual filing trend
Filings rose sharply to a 2018 peak of 130 records, then moderated through the early 2020s; counts for 2025 and 2026 are incomplete due to publication lag and should not be interpreted as a continued structural decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis and surgery) overwhelmingly dominates the branch mix, reflecting that core sensor and electrode hardware remains the primary patenting battleground; G16H (Healthcare informatics) and A61N (Electrotherapy) are the next largest branches, pointing to a secondary wave of software and therapy-integration filings.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Wire Free Self-Contained Single or Multi-Lead Ambu…
A device, method and system are provided to continuously store and analyze single or multi-lead ambulatory ECG signals. Each ECG device is self-contained, wire-free, reusable and capable of non-invasive continuous recording, analyzing and indexing of ECG data independently. A pair of snap connectors on the device body attaches the device to standard ECG… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | World wide patient location and data telemetry sys… | 1,272 |
| 2 | Minimally invasive implantable device for monitori… | 1,125 |
| 3 | World wide patient location and data telemetry sys… | 1,026 |
| 4 | Method and apparatus for health and disease manage… | 781 |
| 5 | Ambulatory monitoring system with real time analys… | 770 |
| 6 | Long-term, ambulatory physiological recorder | 644 |
| 7 | Method and apparatus for determining heart rate va… | 608 |
| 8 | Method and apparatus for measuring heart related p… | 582 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
Four structural observations — maturity, concentration, collaboration, and geography — frame where risk and opportunity sit for teams evaluating entry or expansion in wearable ECG monitoring.
A post-peak field with selective growth pockets
The lifecycle evidence indicates annual filings peaked in 2018 and have eased since, consistent with a Decline stage for raw volume. However, sub-domains such as healthcare informatics (G16H) and AI-assisted interpretation (G06N) have non-trivial and growing representation, suggesting that signal-processing and cloud-analytics layers offer a less crowded entry surface than core hardware.
Decline stage · 2018 peakFirst-tier incumbents hold deep A61B 5 positions
The top five filers account for 40% of the hundred largest filers’ combined total. Bardy Diagnostics alone leads on sheer record count, while Medtronic’s breadth across A61N (electrotherapy) and A61B 5 signals a dual hardware-therapy strategy. Teams entering the space should anticipate dense prior art in patch-electrode and ambulatory recording claims.
40% top-5 shareOne notable co-filing partnership identified: BodyMedia and Virginia Commonwealth University
The only documented co-applicant collaboration in evidence is between BodyMedia and Virginia Commonwealth University, which jointly filed 16 patent records. This is a relatively thin collaboration network for a field of this size, suggesting that most players are innovating independently rather than through formal research partnerships — an observation that may reflect the proprietary nature of clinical-grade ECG algorithm development.
16 co-filed recordsUS-centric portfolio strategy with selective PCT and European extension
The United States is the dominant filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). Germany, India, and Canada represent meaningful secondary markets. China and Japan show comparatively low filing counts, which may indicate that leading US players have not fully internationalized their protection strategies — a potential vulnerability if Asian device manufacturers accelerate their own programs.
US-dominant · low Asia coverageGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| BodyMedia Inc. | Virginia Commonwealth University | 16 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Bardy Diagnostics and AliveCor represent contrasting portfolio trajectories
The two featured players illustrate the difference between an established, volume-heavy incumbent whose recent filing pace has slowed and a challenger showing strong recent momentum.
Bardy Diagnostics Inc.
With 202 patent records, Bardy Diagnostics holds the largest portfolio among all ranked filers, concentrated almost entirely in A61B 5 (core cardiac diagnosis hardware), with secondary positions in G16H 40 (healthcare informatics) and G06F 21 (data processing). Recent filing momentum is down 62% versus the prior period, suggesting the core hardware portfolio has reached a degree of completion and emphasis may be shifting to portfolio maintenance or adjacent claims.
families: 202AliveCor Inc.
AliveCor holds 52 patent records with a technology focus on A61B 5 complemented by G16Z 99 (specific-application computing) and G16H 50 (healthcare informatics analytics), reflecting a consumer-facing software-hardware integration strategy. Recent filing momentum is up 91% versus the prior period — the strongest growth rate among the tracked leaders — indicating active and accelerating portfolio expansion in algorithm and app-layer claims.
families: 52| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Bardy Diagnostics Inc. | 21 | ▼ -62% |
| Medtronic Inc. | 3 | ▲ new entrant |
| Koninklijke Philips NV | 15 | ▲ new entrant |
| Medicomp Inc. | 1 | ▲ new entrant |
| AliveCor Inc. | 21 | ▲ +91% |
| Spangler Scientific LLC | 3 | ▲ new entrant |
Under-served branches adjacent to the core diagnostic hardware cluster
Several IPC branches appear at lower relative share alongside the dominant A61B class. Two of these are worth watching because they combine relative sparsity with clear technical relevance to next-generation wearable ECG systems.
G06N · AI-based computing models
With 32 patent records, AI-model computing represents a small share of the total branch activity despite the widespread industry discussion of on-device arrhythmia detection and federated learning for ECG interpretation. The sparsity is notable given that AliveCor and Spangler Scientific have already begun building informatics-adjacent claims. Teams with proprietary ECG neural-network architectures or edge-inference methods may find relatively open claim space here, particularly for real-time, low-power inference on wrist-worn hardware.
Search this in Eureka →H04W · Wireless communication networks
Only 35 patent records cover wireless networking in the context of wearable ECG, despite Bluetooth Low Energy, ultra-low-power protocols, and mesh-network cardiac monitoring being active engineering challenges. Q Tec Systems has filed in H04L (digital transmission) alongside A61B 5, but dedicated H04W work on power-optimized ECG data relay remains sparse. An entry focused on novel MAC-layer or adaptive duty-cycling protocols for continuous cardiac telemetry could find meaningful white space here.
Search this in Eureka →How leading filers differ by technology route
Strength of each leader across the main technology routes.
| Player | A61B 5 · Diagnosis & surgery | A61N 1 · Electrotherapy & radiation therapy | G16H 40 · Healthcare informatics | G16H 50 · Healthcare informatics | G06F 19 · Electric digital data processing |
|---|---|---|---|---|---|
| Medtronic Inc. | Strong · 108 | Strong · 120 | Emerging · 7 | Absent | Emerging · 8 |
| Bardy Diagnostics Inc. | Strong · 202 | Absent | Emerging · 20 | Absent | Absent |
| Koninklijke Philips NV | Strong · 85 | Absent | Emerging · 11 | Emerging · 6 | Emerging · 7 |
| Medicomp Inc. | Strong · 71 | Absent | Absent | Absent | Absent |
| AliveCor Inc. | Strong · 50 | Absent | Emerging · 9 | Moderate · 12 | Absent |
| Spangler Scientific LLC | Strong · 30 | Absent | Moderate · 10 | Moderate · 10 | Absent |
| Q Tec Systems | Strong · 29 | Absent | Strong · 15 | Absent | Moderate · 6 |
Frequently asked questions
Bardy Diagnostics Inc. holds the largest portfolio among the top 100 ranked filers, with 202 patent records, concentrated in the A61B 5 (cardiac diagnosis and surgery) class.
Annual filing volume peaked in 2018 at 130 patent records. Since then, volume has moderated; counts for 2025 and 2026 are affected by publication lag and should not be interpreted as a definitive trend.
The United States is by far the most active jurisdiction, followed by Europe (EPO) and WIPO (PCT). Germany, India, and Canada are meaningful secondary markets. China and Japan show comparatively low filing counts.
A61B (Diagnosis and surgery) dominates the branch mix. G16H (Healthcare informatics) and A61N (Electrotherapy and radiation therapy) are the next largest branches, reflecting a secondary wave of software and therapy-integration filings.
AliveCor shows the strongest upward momentum among tracked leaders, with recent filings up 91% versus the prior period. Medtronic, Koninklijke Philips, Medicomp, and Spangler Scientific are each classified as new entrants in the recent window. Bardy Diagnostics, by contrast, shows a 62% decline in recent filing pace.
AI-based computing models (G06N, 32 patent records) and wireless communication networks (H04W, 35 patent records) show the largest gap between their technical relevance to wearable ECG systems and their current patent activity, making them the most noteworthy adjacent branches identified in the evidence.
Ready to map your own wearable ECG patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.